| |
This whitepaper provides insight into the basic principles of longitudinal qualitative research, which can guide development efforts and inform communication strategies for a patient centric approach in any therapy area. Learn More. 
|
|
Today's Big NewsSep 23, 2022 |
| By Nick Paul Taylor Pfizer is finally nearly ready to resume dosing in its phase 3 hemophilia A gene therapy trial. Six months after the FDA lifted the clinical hold on the study, trial sites are set to resume enrollment with a view to restarting dosing in October. |
|
|
|
By Nick Paul Taylor Good, but not good enough. That is the verdict AstraZeneca reached after seeing phase 2b data on its Ionis Pharmaceuticals-partnered cholesterol drug ION449, which comfortably beat placebo but fell short of the bar for further development. |
By Gabrielle Masson An FDA advisory committee has rejected Spectrum’s lung cancer hopeful Pozenveo, citing efficacy concerns. |
By James Waldron Ferring Pharmaceuticals’ biotherapeutic passed an FDA committee vote despite some skepticism from a handful of members, setting up the asset for potential approval to treat C. difficile infection. |
By Gabrielle Masson The botulinum toxin family of treatments may be best known for aesthetic applications like Botox. But in Aeon Biopharma's case, its candidate ABP-450 hit its main goals in a phase 2 trial for a rare neck muscle disorder. |
By Teresa Carey This week on "The Top Line," we'll discuss how two Big Pharma companies, GSK and Takeda, made moves this week to bolster their environmental sustainability efforts. We'll discuss their strategies and what we can expect for the future. |
By Fraiser Kansteiner With Eli Lilly’s latest Type 2 diabetes launch and obesity hopeful in the running to become “the biggest drug ever,” an approval for donanemab—the company’s experimental antibody effort against Alzheimer’s disease—would simply be “icing on the cake” for investors. That's according to analysts at UBS. |
By Conor Hale The watchdog office reviewed the FDA’s embrace of “regulatory flexibility” and its use of emergency use authorizations during the first months of 2020, at a time when no coronavirus tests were available anywhere in the country. |
By Zoey Becker,Kevin Dunleavy,Fraiser Kansteiner,Angus Liu CDC data show that a new variant called BF.7 has doubled its incidence nationally over the last two weeks. Pfizer is updating a vaccine order with the U.S. Plus more. |
By Anastassia Gliadkovskaya The Long COVID Research Initiative aims to hasten research and clinical trials for long COVID by soliciting private backers and connecting researchers and clinicians with patients. |
By Gabrielle Masson,Fraiser Kansteiner Maxwell Biosciences has added three new senior executives to its team as it aims to shed its preclinical status. |
By Angus Liu Moderna is considering building a manufacturing plant in Japan, its CEO says. Takeda has offloaded an unwanted cancer drug to Puma Biotechnology. Everest Medicines hired Gilead's former China head as its new CEO. And more. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we'll discuss how two Big Pharma companies, GSK and Takeda, made moves this week to bolster their environmental sustainability efforts. We'll discuss their strategies and what we can expect for the future. |
|
|---|
|
|
eBook Improve your congress competitive intelligence and cut down costs by 50% Sponsored by: Ferma.AI, a Product of ZoomRx |
Executive Summary How a new app brings the power of CRM to a leading lab instruments provider’s field service engineers Sponsored by: Cognizant |
eBook Improve patient engagement, adherence, and outcomes Sponsored by: Health Catalyst |
Whitepaper Supporting your product development programme through experience, expertise, and efficiency. Sponsored by: Almac Pharma Services |
Video Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
Video Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
Whitepaper How can we predict the ability of a preclinical drug to inadvertently cause or intentionally inhibit cytokine secretion and T cell activation Sponsored by: ReachBio | The Cell Biology Experts™ |
Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Whitepaper Read our whitepaper and dive into the way healthcare providers can digitally transform day-to-day work by streamlining costs and increasing agility by removing manual paper burdens. Sponsored by: DocuSign |
Research Learn how a private health insurance company uses analytics to deliver exceptional service to its employees and members Sponsored by: Genpact |
Whitepaper This paper explores how Medical Affairs is increasingly playing a key leadership role in evidence planning and generation (part 3 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
Research TwinRCTs require fewer patients and shorten trial timelines for rare neurodegenerative diseases. Sponsored by: Unlearn |
Multimedia ZS helps life sciences companies shape the future of medicine by turning healthcare data into transformative insights. Discover the power of R&D innovation Sponsored by: ZS |
| |
|
